Catalent Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CATALENT PHARMA
CATALENT PHARMA has one approved drug.
Summary for Catalent Pharma
| US Patents: | 0 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| PTAB Cases with Catalent Pharma as petitioner: | See PTAB cases with Catalent Pharma as petitioner |
Drugs and US Patents for Catalent Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalent Pharma | LORATADINE | loratadine | CAPSULE;ORAL | 215127-001 | Feb 28, 2025 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
